{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T22:22:05Z","timestamp":1767997325505,"version":"3.49.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2004,6,7]],"date-time":"2004-06-07T00:00:00Z","timestamp":1086566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2004,6,7]],"date-time":"2004-06-07T00:00:00Z","timestamp":1086566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2004,7,1]]},"DOI":"10.1038\/sj.bmt.1704521","type":"journal-article","created":{"date-parts":[[2004,6,21]],"date-time":"2004-06-21T08:16:12Z","timestamp":1087805772000},"page":"51-56","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["A randomized trial of amifostine as a cytoprotectant for patients receiving myeloablative therapy for allogeneic hematopoietic stem cell transplantation"],"prefix":"10.1038","volume":"34","author":[{"given":"W Y K","family":"Hwang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L-P","family":"Koh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H J","family":"Ng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P H C","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C T H","family":"Chuah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S C","family":"Fook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Chow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K W","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C H","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y-T","family":"Goh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2004,6,7]]},"reference":[{"key":"BF1704521_CR1","first-page":"309","volume-title":"Radiation Sensitizers","author":"DE Davidson","year":"1980","unstructured":"Davidson DE, Grenan MM, Sweeney TR . Biological characteristics of some improved radioprotectors. In: Brady LW (ed.). Radiation Sensitizers. Masson: New York, 1980; pp 309\u2013320."},{"key":"BF1704521_CR2","first-page":"3","volume":"4","author":"TH Wasserman","year":"1981","unstructured":"Wasserman TH, Phillips TL, Ross G et al. Differential protection against cytotoxic chemotherapeutic effects on bone marrow CFUs by WR-2721. Cancer Clin Trials 1981; 4: 3\u20136.","journal-title":"Cancer Clin Trials"},{"key":"BF1704521_CR3","first-page":"211","volume":"3","author":"JM Yuhas","year":"1980","unstructured":"Yuhas JM, Spellman JM, Culo F . The role of WR-2721 in radiotherapy and\/or chemotherapy. Cancer Clin Trials 1980; 3: 211\u2013216.","journal-title":"Cancer Clin Trials"},{"issue":"Suppl. 1","key":"BF1704521_CR4","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1016\/0959-8049(95)00146-A","volume":"31A","author":"L Douay","year":"1995","unstructured":"Douay L, Hu C, Giarratana MC, Gorin NC . Amifostine (WR-2721) protects normal haematopoietic stem cells against cyclophosphamide derivatives' toxicity without compromising their antileukaemic effects. Eur J Cancer 1995; 31A (Suppl. 1): S14\u2013S16.","journal-title":"Eur J Cancer"},{"key":"BF1704521_CR5","first-page":"23","volume":"47","author":"PM Calabro-Jones","year":"1985","unstructured":"Calabro-Jones PM, Fahey RC, Smoluk GD et al. Alkaline phosphatase promotes radioprotection and accumulation of WR-1065 in V79-171 cells incubated in medium containing WR-2721. Int J Radiat Biol 1985; 47: 23\u201327.","journal-title":"Int J Radiat Biol"},{"key":"BF1704521_CR6","first-page":"290","volume":"36","author":"JL Yang","year":"1996","unstructured":"Yang JL, Fernandes DJ, Speicher L et al. Biochemical determinants of the cytoprotective effect of amifostine. Proc Am Assoc Cancer Res 1996; 36: 290 (abstr 1725).","journal-title":"Proc Am Assoc Cancer Res"},{"issue":"Suppl. 11","key":"BF1704521_CR7","first-page":"16","volume":"21","author":"L Douay","year":"1994","unstructured":"Douay L, Hu C, Giarratana MC, Gorin NC . Comparative effects of amifostine (Ethyol) on normal hematopoietic stem cells vs human leukemic cells during ex vivo purging in autologous bone marrow transplants. Semin Oncol 1994; 21 (Suppl. 11): 16\u201320.","journal-title":"Semin Oncol"},{"key":"BF1704521_CR8","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1038\/sj.bmt.1702694","volume":"26","author":"S Cronin","year":"2000","unstructured":"Cronin S, Uberti JP, Ayash LJ et al. Use of amifostine as a chemoprotectant during high-dose chemotherapy in autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2000; 26: 1247\u20131249.","journal-title":"Bone Marrow Transplant"},{"key":"BF1704521_CR9","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1097\/00000421-200008000-00019","volume":"23","author":"TR Chauncey","year":"2000","unstructured":"Chauncey TR, Gooley TA, Lloid ME et al. Pilot trial of cytoprotection with amifostine given with high-dose chemotherapy and autologous peripheral blood stem cell transplantation. Am J Clin Oncol 2000; 23: 406\u2013411.","journal-title":"Am J Clin Oncol"},{"key":"BF1704521_CR10","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","volume":"47","author":"AB Miller","year":"1981","unstructured":"Miller AB, Hoogstraten B, Staquet M, Winkler A . Reporting results of cancer treatment. Cancer 1981; 47: 207\u2013214.","journal-title":"Cancer"},{"key":"BF1704521_CR11","unstructured":"NCI\/NIH Common Toxicity Criteria v2.0 (CTC) 1998."},{"key":"BF1704521_CR12","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"E Kaplan","year":"1958","unstructured":"Kaplan E, Meier P . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457\u2013481.","journal-title":"J Am Stat Assoc"},{"key":"BF1704521_CR13","first-page":"163","volume":"50","author":"N Mantel","year":"1966","unstructured":"Mantel N . Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163\u2013170.","journal-title":"Cancer Chemother Rep"},{"key":"BF1704521_CR14","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1056\/NEJM198603203141201","volume":"31","author":"R Storb","year":"1986","unstructured":"Storb R, Deeg HJ, Whitehead J et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986; 31: 729\u2013735.","journal-title":"N Engl J Med"},{"key":"BF1704521_CR15","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1093\/annonc\/mdg301","volume":"14","author":"D Lorusso","year":"2003","unstructured":"Lorusso D, Ferrandina G, Greggi S et al. Multicenter Italian Trials in Ovarian Cancer investigators. Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients. Ann Oncol 2003; 14: 1086\u20131093.","journal-title":"Ann Oncol"},{"key":"BF1704521_CR16","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1016\/S0360-3016(03)00187-1","volume":"56","author":"H Athanassiou","year":"2003","unstructured":"Athanassiou H, Antonadou D, Coliarakis N et al. Oncology Hellenic Group. Protective effect of amifostine during fractionated radiotherapy in patients with pelvic carcinomas: results of a randomized trial. Int J Radiat Oncol Biol Phys 2003; 56: 1154\u20131160.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"Suppl.","key":"BF1704521_CR17","doi-asserted-by":"publisher","first-page":"S216","DOI":"10.1016\/S0360-3016(03)01029-0","volume":"57","author":"M Werner-Wasik","year":"2003","unstructured":"Werner-Wasik M, Scott C, Movsas B et al. Amifostine as mucosal protectant in patients with locally advanced non-small cell lung cancer (NSCLC) receiving intensive chemotherapy and thoracic radiotherapy (RT): results of the radiation therapy oncology group (RTOG) 98-01 study. Int J Radiat Oncol Biol Phys 2003; 57 (Suppl.): S216.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"BF1704521_CR18","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/S1470-2045(03)01132-X","volume":"4","author":"DM Brizel","year":"2003","unstructured":"Brizel DM, Overgaard J . Does amifostine have a role in chemoradiation treatment? Lancet Oncol 2003; 4: 378\u2013381.","journal-title":"Lancet Oncol"},{"issue":"Suppl. 19","key":"BF1704521_CR19","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1053\/sonc.2002.37356","volume":"29","author":"A Giatromanolaki","year":"2002","unstructured":"Giatromanolaki A, Sivridis E, Maltezos E, Koukourakis ML . Down-regulation of intestinal-type alkaline phosphatase in the tumor vasculature and stroma provides a strong basis for explaining amifostine selectivity. Semin Oncol 2002; 29 (Suppl. 19): 14\u201321.","journal-title":"Semin Oncol"},{"key":"BF1704521_CR20","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/sj.bmt.1703757","volume":"30","author":"C Thieblemont","year":"2002","unstructured":"Thieblemont C, Dumontet C, Saad H et al. Amifostine reduces mucosal damage after high-dose melphalan conditioning and autologous peripheral blood progenitor cell transplantation for patients with multiple myeloma. Bone Marrow Transplant 2002; 30: 769\u2013775.","journal-title":"Bone Marrow Transplant"},{"key":"BF1704521_CR21","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1054\/bjoc.2000.1611","volume":"84","author":"JT Hartmann","year":"2001","unstructured":"Hartmann JT, von Vangerow A, Fels LM et al. A randomized trial of amifostine in patients with high-dose VIC chemotherapy plus autologous blood stem cell transplantation. Br J Cancer 2001; 84: 313\u2013320.","journal-title":"Br J Cancer"},{"key":"BF1704521_CR22","doi-asserted-by":"crossref","unstructured":"Phillips II GL . The potential of amifostine in high-dose chemotherapy and autologous hematopoietic stem cell transplantation. Semin Oncol 2002: (Suppl. 19): 53\u201356.","DOI":"10.1053\/sonc.2002.37367"},{"key":"BF1704521_CR23","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1016\/S0301-472X(99)00086-7","volume":"27","author":"A Poloni","year":"1999","unstructured":"Poloni A, Leoni P, Curzi L et al. Ex vivo pharmacological purging of leukapheresis collections with nitrogen mustard: amifostine pretreatment improves both early and late peripheral blood progenitor cell recovery. Exp Hematol 1999; 27: 1548\u20131556.","journal-title":"Exp Hematol"},{"key":"BF1704521_CR24","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1089\/152581601317210980","volume":"10","author":"C Emmanouilides","year":"2001","unstructured":"Emmanouilides C, Territo M, Andrey J, Mason J . A randomized phase II study of amifostine used as stem cell protectant in non-Hodgkin lymphoma patients receiving cisplatin-based salvage chemotherapy prior to stem cell transplant. J Hematother Stem Cell Res 2001; 10: 887\u2013893.","journal-title":"J Hematother Stem Cell Res"},{"key":"BF1704521_CR25","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s00277-002-0538-4","volume":"81","author":"O Rick","year":"2002","unstructured":"Rick O, Beyer J, Schwella N, Siegert W . Influence of amifostine on reconstitution of lymphocyte subpopulations after conventional- and high-dose chemotherapy in patients with germ cell tumor. Ann Hematol 2002; 81: 717\u2013722.","journal-title":"Ann Hematol"},{"key":"BF1704521_CR26","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/0163-7258(88)90061-7","volume":"39","author":"LM Shaw","year":"1988","unstructured":"Shaw LM, Glover DJ, Turrisi A et al. Pharmocokinetics of WR-2721. Pharmacol Ther 1988; 39: 195\u2013201.","journal-title":"Pharmacol Ther"},{"key":"BF1704521_CR27","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1007\/s005200050253","volume":"7","author":"A Heimdahl","year":"1999","unstructured":"Heimdahl A . Prevention and management of oral infections in cancer patients. Support Care Cancer 1999; 7: 224\u2013228.","journal-title":"Support Care Cancer"},{"key":"BF1704521_CR28","first-page":"73","volume":"173","author":"CE Edmiston Jr","year":"1991","unstructured":"Edmiston Jr CE, Condon RE . Bacterial translocation. Surg Gynecol Obstet 1991; 173: 73\u201383.","journal-title":"Surg Gynecol Obstet"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/1704521.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1704521","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1704521.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T23:18:19Z","timestamp":1648077499000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/1704521"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,6,7]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,7,1]]}},"alternative-id":["BF1704521"],"URL":"https:\/\/doi.org\/10.1038\/sj.bmt.1704521","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,6,7]]},"assertion":[{"value":"28 February 2003","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2004","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2004","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}